Pakistani Patient's CAR-T Recovery in Shanghai (2026): What Jiahui International Cancer Center Did Differently

What CAR-T Therapy Is — and Why the Late-Stage Lymphoma Case Is Hard

CAR-T therapy is a form of immunotherapy in which a patient's own T-cells — a type of white blood cell — are collected through a process called leukapheresis, shipped to a specialized manufacturing facility, genetically engineered to express a chimeric antigen receptor that recognizes a protein (most commonly CD19) on the surface of the patient's cancer cells, expanded, and then reinfused into the patient. The cells then proliferate inside the body and attack the cancer. The whole cycle, from collection to infusion, usually takes three to six weeks depending on the manufacturer and the patient's disease status.

The hard part of CAR-T is not the manufacturing — although manufacturing capacity is still a global bottleneck. The hard part is everything that surrounds the infusion: lymphodepleting chemotherapy to make space for the new cells, vigilant monitoring for cytokine release syndrome (CRS, an inflammatory storm that can be life-threatening if not treated quickly), immune effector cell-associated neurotoxicity syndrome (ICANS), infection risk during the recovery window, and the management of patients who arrive with extensive tumor burden, poor organ function, or a long history of prior treatment failure. These are exactly the conditions Muhammad was in.

For diffuse large B-cell lymphoma (DLBCL) — Muhammad's diagnosis — CAR-T is no longer experimental. Three products have been approved in major markets: axicabtagene ciloleucel (Yescarta), tisagenlecleucel (Kymriah), and lisocabtagene maraleucel (Breyanzi). In registrational trials for CD19 CAR-T in DLBCL, roughly 50-60% of patients with relapsed or refractory disease achieve a complete response after infusion, and a meaningful share of those complete responses last. The US National Cancer Institute lists CAR-T as a standard option for DLBCL that has failed two or more lines of therapy, and several real-world analyses have shown comparable response rates outside clinical trials when centers are experienced.

What Muhammad's case illustrates is the difference between "CAR-T is available somewhere" and "CAR-T can be delivered safely to a sick patient who has flown in from another country, with a heavy tumor burden, on high-dose opioids, and with cultural and language needs." That is a service-line question, not a science question.

Jiahui International Cancer Center: What the Hospital Brings to the Table

Jiahui International Cancer Center is part of Jiahui Health, a Shanghai-based private hospital network with locations in Shanghai (Yangpu, Jing'an), Suzhou, Hangzhou, Shenzhen, Kunshan, and Hong Kong. The international hospital in Shanghai's Yangpu district — Jiahui International Hospital — is the referral hub for complex cases, and the cancer center sits inside it. The hospital was founded as a collaboration with Massachusetts General Hospital (a Harvard Medical School teaching hospital), and it holds Joint Commission International (JCI) accreditation, which is the international standard most foreign patients and insurers look for first.

For CAR-T, the clinical lead is Dr. Hao Siguo, the chief hematology consultant. According to the Jiahui case narrative, Dr. Hao has been working on CAR-T clinical research and application since 2017 and has "pioneered CAR-T cell therapy for lymphoma and multiple myeloma" at the center, with a particular focus on complex and high-risk cases. The center also draws on a multidisciplinary team — the case credits Dr. Dong Yan, a medical oncologist, for designing the bridging therapy — and the hospital's international patient services team coordinates the pre-arrival process.

For an international patient like Muhammad, the practical difference between a Chinese public tertiary center and Jiahui is not the technology — top public centers in Beijing, Shanghai, and Guangzhou also offer CAR-T, and at comparable or lower prices. It is the speed of consultation, the willingness to do remote pre-admission workup, the in-house translation, the cultural and religious accommodations (halal food in this case), and the explicit international patient office. Public hospitals in China can be excellent on the medicine and crowded on the logistics. Private hospitals like Jiahui sell the bundle.

Muhammad's Timeline, Day by Day

For an international patient considering a similar path, the Jiahui case is unusually well-documented. The published account lays out a 65-day arc from first contact to discharge, with the cell therapy itself fitting into a roughly three-week inpatient window.

There is one clinical point worth flagging. The bridging therapy — chemotherapy plus radiotherapy given between cell collection and cell infusion — is not a small thing. It is exactly the kind of decision that separates a CAR-T center doing volume from a center that is genuinely tailoring the regimen to the patient. A heavy tumor burden is the single biggest predictor of severe CRS and ICANS after infusion, and the only proven way to blunt that risk is to reduce the burden before Day 0. Jiahui's lead oncologist, Dr. Dong Yan, made that call explicitly in the published case narrative, and the outcome — mild CRS, no severe neurotoxicity — is consistent with that strategy working.

What Does CAR-T Cost in China vs the US, Singapore, and India?

Cost is the part of the China CAR-T story that international patients usually fixate on, and the difference is real but not as wide as it was three years ago. The US list price for a single infusion of axicabtagene ciloleucel or tisagenlecleucel is in the $400,000 to $1.5 million range before any hospital or complication fees, although most insured US patients pay a fraction of that after insurance negotiations and outcomes-based contracts.

China is materially cheaper, but the published prices vary widely depending on whether you are looking at a domestic Chinese product (relmacabtagene, equecabtagene, etc.) or a Western product manufactured locally (Yikaida, the Fosun-Kite version of axicabtagene). The table below uses the ranges we have seen cited in Chinese clinical journals, hospital pricing pages, and the Jiahui-style private hospital experience for 2025 and 2026.

The single most important caveat here: the published Jiahui case does not say what Muhammad's family paid. The price ranges in the table are drawn from the broader 2025-2026 China CAR-T market, not from a Jiahui invoice. If you are planning a similar trip, the only reliable number is the one you receive in writing from the hospital after case review.

What the International Patient Path Looks Like in Practice

For patients from Pakistan, Bangladesh, Sri Lanka, the UAE, Saudi Arabia, Central Asian countries, and parts of Africa — the markets Jiahui and other Shanghai private hospitals most actively court — the practical path is more standardized than it used to be. The Jiahui case, combined with our prior reporting on CAR-T in China and the China Hospitals Guide advisory experience, suggests the following sequence for a patient considering autologous CAR-T at a Shanghai center:

• Step 1 — Local workup and outbound approval. Confirm that the patient's lymphoma is indeed refractory (failed at least two prior lines of therapy) and that a transplant is not a viable option. In Pakistan, the national medical board must formally approve outbound treatment before the patient can apply for a medical visa.
• Step 2 — Remote consultation and case review. The hospital's international patient office collects pathology slides, imaging (usually DICOM files on a CD or a secure upload link), and a clinical summary. A hematologist reviews the case and either accepts or declines. Accepted cases usually get a quote and a medical visa invitation letter within one to two weeks.
• Step 3 — Medical visa and travel. China's medical visa (an M visa with a medical invitation letter) is straightforward once the hospital's invitation is in hand. Total processing time is typically 5-10 working days in most countries. Family members can travel on companion visas.
• Step 4 — On-site workup, cell collection, bridging therapy. Once in Shanghai, the patient undergoes confirmation imaging and bloodwork, leukapheresis, and (if tumor burden is high) bridging therapy while the CAR-T cells are manufactured. Expect this phase to take 2-3 weeks.
• Step 5 — Lymphodepletion and infusion. Three days of conditioning chemotherapy, then the infusion. Hospital stay is usually 10-14 days, longer if there is any significant CRS or ICANS.
• Step 6 — Discharge and remote follow-up. Patients are typically cleared to fly home 7-14 days after a clean discharge. Jiahui's team, like most international-focused centers, coordinates remote follow-up imaging and labs through the referring oncologist back home.

The total time away from home is usually 6-10 weeks, depending on the case complexity and any bridging therapy needs. Budget for at least one companion to travel with the patient.

Other Chinese Hospitals Doing International CAR-T

Jiahui is not the only option. The broader picture for international patients considering CAR-T in China includes several other active centers, each with slightly different strengths.

• Shanghai — Fudan University Shanghai Cancer Center — one of China's largest public oncology centers, with active CAR-T clinical trials and a high-volume hematology department. Public-hospital pricing; international patient experience is less bundled than at private centers.
• Beijing — Chinese Academy of Medical Sciences Cancer Hospital (National Cancer Center) — the top-tier public option in the north. Active in CAR-T for lymphoma, multiple myeloma, and selected solid tumors in clinical trials.
• Guangzhou — Sun Yat-sen University Cancer Center — high-volume CAR-T center in southern China, convenient for patients from Southeast Asia.
• Wuhan — Tongji Hospital, Huazhong University of Science and Technology — large hematology department with active CAR-T program.
• Hangzhou — Zhejiang University First Affiliated Hospital — among the earliest Chinese centers to run commercial CAR-T programs, including for multiple myeloma.
• Boao Lecheng, Hainan — multiple centers — the special medical zone can import Western CAR-T products that are not yet approved elsewhere in mainland China. Relevant for patients who specifically need a Western-manufactured product at Chinese prices.

Public centers in China typically quote 30-50% below the private international hospital price for the same procedure, with the trade-off being less coordinated international patient support, longer initial consultation wait times, and a more crowded in-hospital experience. The right choice depends on the patient's case complexity, language and cultural needs, and budget.

What's Next for Cell Therapy in China

Three trends are worth watching in the second half of 2026 and into 2027.

First, solid tumor CAR-T. Most of the current CAR-T market is in blood cancers — lymphomas, leukemias, multiple myeloma — because the CD19 and BCMA targets are well understood and the cancer cells are accessible to circulating T-cells. Solid tumors (lung, breast, colon, pancreatic) are harder because the tumor microenvironment suppresses T-cell function and because the right target proteins are harder to find. China has been pushing hard on solid-tumor CAR-T: the NMPA approved what the field is calling the first commercial solid-tumor CAR-T in 2026, and several Chinese companies — including Oricell Therapeutics, which closed a $110 million round in 2026 specifically for solid-tumor CAR-T — are running active clinical programs.

Second, allogeneic ("off-the-shelf") CAR-T. All the products discussed above are autologous, meaning the cells come from the patient. That creates the multi-week manufacturing window, the leukapheresis step, and the dependence on the patient's T-cells being healthy enough to engineer. Allogeneic CAR-T uses donor cells, manufactured in advance and stored until needed — closer to a traditional drug. Several Chinese biotechs have allogeneic programs in early trials.

Third, global licensing of Chinese CAR-T products. BioOra's 2026 deal to license China's atla-cel for global development was an early signal that Chinese-engineered CAR-T products are starting to be taken seriously outside China. As more Chinese products generate strong Phase 2 and Phase 3 data, the international licensing and partnership pipeline is likely to accelerate, and the price of CAR-T in Western markets will come under pressure.

What Makes the Chinese CAR-T Data Work as a Reference

If you are a patient or a family member evaluating CAR-T in China, three things from Muhammad's case are worth keeping in mind.

First, the medical decision is still about eligibility and disease biology, not geography. CAR-T works for CD19-positive B-cell lymphomas that have failed at least two prior lines of therapy. If the patient is in that window, the next question is which center has the most experience with the specific disease subtype and the most robust bridging and toxicity management protocols. Jiahui is one of several good answers; it is not the only one.

Second, the international patient experience is the differentiator, not the price alone. The dollar savings on a Chinese CAR-T product vs a US list price are real, but they evaporate quickly if the case is mismanaged, if the bridging therapy is skipped, or if the post-discharge follow-up is not coordinated with the home oncologist. The Jiahui-style bundle — remote consultation, visa coordination, halal food, professional translation, structured discharge planning, and remote follow-up — is what you are paying the private hospital premium for.

Third, the field is moving fast. The case we are writing about today — autologous CD19 CAR-T for relapsed DLBCL at a Shanghai private hospital — is the current state of the art for many patients, but it is not the end state. Allogeneic products, solid-tumor CAR-T, and bispecific antibodies (such as the ivonescimab story we covered on May 27) are all in active clinical pipelines in China. The cost-versus-outcomes picture is going to look different in 2027, and a case that looks optimal today may not be the recommended path in two years.